Sam's (Afrezzauser) post one year later....
Aug 2, 2014 13:23:52 GMT -5
4Balance and daduke38 like this
Post by joeypotsandpans on Aug 2, 2014 13:23:52 GMT -5
I took this excerpt from Afrezzauser's thread from about a year ago...it made me think about the label and what they (FDA) wouldn't allow as far as the ultra rapid acting and the fact that they would not allow MNKD to state that there was an advantage to the current two fast acting insulins in Novolog and Humalog, here is the excerpt:
Aug 20, 2013 at 7:22am brentie likes this.
ReplyQuote like Post Options
Post by afrezzauser on Aug 20, 2013 at 7:22am
I wish the FDA would do a 6 month follow up to see how all the Afrezza patients are doing when back on the Novolog. That would be the true sign of how well Afrezza works. I got to 6s on Afrezza really without trying. To achieve the same results with current treatment you would have to live and breathe diabetes every day. What I mean is I do nto want to baby sit this disease hours a day. I need to be back on Afrezza where I can achieve a1c of 6s without counting carbs or planning meals.
Read more: mnkd.proboards.com/thread/84/#ixzz39G7urnEg
Well we are now just about 1 yr. from this post and it would be interesting to see how exactly the trial participants are doing since they had to go back onto the other two insulins.....You can bet your bottom dollar that IMO there will be positive changes to the label down the road...in another thread response, Sam said he would much rather run the risk of having a higher A1c such as in the 8's then worrying about passing away in the night.
I cannot thank Sam enough for his posts and youtube of the dreamboat demonstration along with his testimony at his own expense at the ADCOM....it was his posts in the same context of what BE stated in his SA article referencing the shortsighted aspect of the shorts where listening to the patients is far more important than listening to the so called analysts, etc. that ultimately convinced me to go all in on my investment. It gave me a tremendous insight into the benefits of Afrezza along with its potential to not only commit my own funds but in with great confidence encourage others to invest and back the company as well. How do you think NOVO and LLY would feel about a follow up with those trial participants? Eventually the FDA will get it right when it comes to the labeling IMO
Aug 20, 2013 at 7:22am brentie likes this.
ReplyQuote like Post Options
Post by afrezzauser on Aug 20, 2013 at 7:22am
I wish the FDA would do a 6 month follow up to see how all the Afrezza patients are doing when back on the Novolog. That would be the true sign of how well Afrezza works. I got to 6s on Afrezza really without trying. To achieve the same results with current treatment you would have to live and breathe diabetes every day. What I mean is I do nto want to baby sit this disease hours a day. I need to be back on Afrezza where I can achieve a1c of 6s without counting carbs or planning meals.
Read more: mnkd.proboards.com/thread/84/#ixzz39G7urnEg
Well we are now just about 1 yr. from this post and it would be interesting to see how exactly the trial participants are doing since they had to go back onto the other two insulins.....You can bet your bottom dollar that IMO there will be positive changes to the label down the road...in another thread response, Sam said he would much rather run the risk of having a higher A1c such as in the 8's then worrying about passing away in the night.
I cannot thank Sam enough for his posts and youtube of the dreamboat demonstration along with his testimony at his own expense at the ADCOM....it was his posts in the same context of what BE stated in his SA article referencing the shortsighted aspect of the shorts where listening to the patients is far more important than listening to the so called analysts, etc. that ultimately convinced me to go all in on my investment. It gave me a tremendous insight into the benefits of Afrezza along with its potential to not only commit my own funds but in with great confidence encourage others to invest and back the company as well. How do you think NOVO and LLY would feel about a follow up with those trial participants? Eventually the FDA will get it right when it comes to the labeling IMO
